R&D of medicines and external diagnostic drugs based on monoclonal antibodies
1)We made the brand new monoclonal antibody (mAb) against a new colorectal cancer (CRC) specific molecule obtained after comprehensive expression analysis between the pure mucoepithelial cells and CRC cell line.
The antigen is circulating in blood stream in patients with CRC and therefore we are developing a new blood test for CRC. Furthermore, we are developing the new antibody therapeutics using the mAb because the mAb appears to possess a robust ADCC function and in vivo antitumor activity.
2)We successfully developed an mAb that reacted only with human fibrin, not with human fibrinogen and cross-reacted with mouse fibrin but not with mouse fibrinogen. The specificity of our mAb differs from existing anti-fibrin mAbs. Namely, the mAb reacts only with fibrin clot, but not with fibrinogen, soluble fibrin, or D-dimer. The anti-fibrin antibody therefore did not make immune complex in the blood stream and circulated in the blood for a long time. We then prepared the antibody drug conjugate (ADC) that is MMAE conjugated anti-fibrin mAb. The ADC may selectively extravasate from leaky tumor vessels, bind to the fibrin network in the stroma and create a scaffold from which effective sustained release of the free MMAE occur. This free MMAE may easily reach the cancer cells by diffusion through the stroma barrier. Another benefit is that MMAE released from the ADC may also attack the vascular endothelial cells.
The company name "RIN " is the abbreviation for Robust Immuno-diagnosis and therapy against malignant Neoplasm.
Another origin of the company name: RIN derives from the name of one of the founders' granddaughter "Rinko".
|Company Name||RIN Institute Inc.|
|Date founded||January 21,2016|
|Company Address||Shintomi Bldg. 3F, 2-5-10, Shintomi, Chuo-ku, Tokyo, 104-0041, Japan|